Pfizer enters weight loss drug market with Novo Nordisk, Eli Lilly
CFOTO | Future Publishing | Getty ImagesAs its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming data on Pfizer's experimental obesity pill, danuglipron, will be crucial in determining how competitive the company can be against the space's dominant players Eli Lilly...